SYBX Synlogic Inc.

4.61
+0.09  (+2%)
Previous Close 4.52
Open 4.57
Price To Book 0.81
Market Cap 146,222,751
Shares 31,718,601
Volume 110,979
Short Ratio
Av. Daily Volume 245,546

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data released July 15, 2019 - well tolerated. Full data to be presented at SSIEM September 3-6, 2019.
SYNB1618
Phenylketonuria (PKU)
Phase 1/2 top-line data due 3Q 2019.
SYNB1020
Cirrhotic patients with elevated ammonia
IND to be filed 2H 2019.
SYNB1891 and atezolizumab
Solid tumors

Latest News

  1. Edited Transcript of SYBX earnings conference call or presentation 8-Aug-19 9:00pm GMT
  2. Synlogic to Present at the 2019 Wedbush PacGrow Healthcare Conference
  3. Synlogic Reports Second Quarter 2019 Financial Results and Provides Program Updates
  4. Microbiome biotechs grapple with how to protect their IP
  5. Synlogic Announces Second Quarter 2019 Conference Call and Webcast
  6. Synlogic Enters Oversold Territory
  7. Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with Phenylketonuria and Guides to Next Phase of Development
  8. American Gene Technologies: The Software Revolution for the Next 100 Years
  9. Synlogic and Ginkgo Bioworks Establish Transformational Platform Collaboration for the Accelerated Development of Novel Synthetic Biotic™ Medicines
  10. Synlogic (SYBX) Enters Cancer Collaboration with Roche
  11. Synlogic Announces Clinical Collaboration to Evaluate SYNB1891 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
  12. Synlogic, Inc. (SYBX) Q1 2019 Earnings Call Transcript
  13. Edited Transcript of SYBX earnings conference call or presentation 9-May-19 9:00pm GMT
  14. Synlogic Reports First Quarter 2019 Financial Results and Provides Business Update
  15. Synlogic Announces First Quarter 2019 Conference Call and Webcast
  16. Synlogic Presents Data Describing a Solid Oral Formulation Process for Synthetic Biotic™ Medicine SYNB1618 for the Treatment of PKU at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
  17. Gut Check: The Bacteria In Your Intestines Could Help Cure Cancer
  18. Could Synlogic, Inc.'s (NASDAQ:SYBX) Investor Composition Influence The Stock Price?
  19. Synlogic to Present Data from New Solid Oral Formulation Process at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
  20. Synlogic Appoints Scott Plevy M.D. as Chief Scientific Officer